• Behavioral Health
  • Clinical Insights
  • Treatment

Uzedy™: Long-acting injection for the treatment of schizophrenia

Jan 31st, 2024

Learn more about this new treatment option for adults living with schizophrenia

Genoa is here to help keep you informed on the latest in behavioral health medications. Read on to learn more about Uzedy™, a new long-acting injectable formulation of risperidone, used to treat schizophrenia in adults.

Overview:

  • Uzedy™ (risperidone) is a long-acting injectable used to treat schizophrenia in adults. It combines the established risperidone molecule – one of the most frequently prescribed atypical antipsychotics for the treatment of schizophrenia[1] – with delivery technology that controls the release of risperidone over time.
  • It’s administered subcutaneously in the abdomen or upper arm every one or two months, depending on the prescription.
  • It comes in a prefilled syringe and is ready to use, not requiring any premixing or reconstitution. As a subcutaneous injection, Uzedy™ is administered with a 5/8-inch needle and the injection volume is low compared to alternative injection options.
  • While the drug does require refrigeration, it may be stored at room temperature for up to 90 days prior to administration. Prior to injection, the dose should be brought to room temperature for at least 30 minutes.
  • There is no oral supplementation or loading dose to start treatment as therapeutic plasma levels establish themselves within six to 24 hours.

Interested in learning more? We’re here to help! Connect with your local Genoa pharmacy team or fill out the form below and we’ll be in touch.

Interested in learning more?

Curious how Uzedy™ can help the people you serve living with schizophrenia? Contact us today and we’ll be in touch.

"*" indicates required fields

Name*
Does your organization currently partner with Genoa?*
This field is for validation purposes and should be left unchanged.

[1] https://www.uzedyhcp.com/features-of-uzedy

Information on Uzedy™ was taken from www.uzedyhcp.com.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Treatment
4 things to know about Spravato® (Intranasal esketamine)

On January 21, 2025, the FDA announced the approval of Spravato® nasal spray as a monotherapy treatment for treatment-resistant depression (TRD), making this medication the first and only monotherapy option...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa’s 2024 Art Celebration: Celebrating the healing power of creativity

“I’ve always expressed myself through my art and learned to use my creativity to inspire others”, says Genoa Healthcare 2024 Art Celebration participant Shanelle G. Genoa’s annual Art Celebration invites...

Partner with Genoa
  • Behavioral Health
  • Clinical Insights
  • Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression

Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...

  • Behavioral Health
  • Clinical Insights
  • Partnering with Genoa
CMS reporting now required: 4 ways Genoa can help

By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...